IVEVF — Inventiva S.A.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1756594 ·
Last close
$3.59
Market Cap
$848.03M
52W High
$5.75
52W Low
$3.59
ADV30
3
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 249,511,000 | 99,312,000 | 278,033,000 |
| Jun 2025 | — | — | — | — | 178,955,000 | 122,076,000 | 187,863,000 |
| Dec 2024 | — | — | — | — | 118,967,000 | 96,563,000 | 225,613,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-354,138,000
Inventory
$0
Receivables
$9,121,000
ST Investments
$131,558,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,761,000
EBITDA
$-132,497,000
Free Cash Flow
$-200,711,632
Enterprise Value
$876,720,832
Total Cash
$99,839,000
Total Debt
$230,890,000
Shares Out
236,220,651
Trailing EPS
$-2.16
Book Value
$-0.17
ROE
—
ROA
-45.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,483,000 | -132,883,000 | -354,138,000 | 249,511,000 | 278,033,000 | — | -104,884,000 |
| Dec 2024 | 9,198,000 | -93,989,000 | -184,212,000 | 118,967,000 | 225,613,000 | — | -85,928,000 |
| Dec 2023 | 17,477,000 | -102,665,000 | -110,426,000 | 69,561,000 | 101,592,000 | — | -81,614,000 |
| Dec 2022 | 12,179,000 | -56,857,000 | -54,274,000 | 116,004,000 | 70,528,000 | — | -44,928,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMPH | Amphastar Pharmaceuticals, Inc. | $825.42M | $18.72 | — |
| OCS | Oculis Holding AG | $823.09M | $13.63 | — |
| TBPH | Theravance Biopharma, Inc. | $877.45M | $16.93 | — |
| ESPR | Esperion Therapeutics, Inc. | $819.46M | $3.18 | — |
| CTMX | CytomX Therapeutics, Inc. | $818.56M | $3.76 | — |
News headlines (Yahoo Finance, 1h cache)
Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants
2026-07-09 20:20 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise Thursday
2026-07-09 15:10 · Yahoo
Results of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026
2026-07-02 20:00 · Yahoo
Inventiva S.A. (IVA) is One of the Best Stocks Under $10 Offering More Than 50% Upside
2026-06-30 16:34 · Yahoo
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)
2026-06-29 13:35 · Yahoo
Claret Capital Partners participates in €130m financing for Inventiva
2026-06-16 09:12 · Yahoo
Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development
2026-06-16 08:52 · Yahoo
Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
2026-06-12 20:00 · Yahoo
Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround
2026-06-11 13:35 · Yahoo
Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026
2026-06-09 20:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.